Flamel Technologies (Nasdaq: FLML) today announced its financial results for the first quarter of 2011. Highlights since the Company’s last conference call include:
-Entering into licensing agreements for two controlled release formulations of molecules with a leading specialty pharmaceuticals company. Flamel will receive $3 million upfront, as well as eventual development milestones and royalties upon sale of the product.
